MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-22-0618

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2022

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.

Baines Andrea C, Ershler Rachel, Kanapuru Bindu, Xu Qing, Shen Guoxiang, Li Liang, Ma Lian, Okusanya Olanrewaju O, Simpson Natalie E, Nguyen Wanda, Theoret Marc R, Pazdur Richard, Gormley Nicole J

Многоцентровое исследованиеСтатьяПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

On August 5, 2020, the FDA granted accelerated approval to belantamab mafodotin-blmf (BLENREP; GlaxoSmithKline) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Substantial evidence of effectiveness was obtained from the phase II, multicenter DREAMM-2 trial. Patients received belantamab mafodotin 2.5 or 3.4 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity. The trial demonstrated an overall response rate of 31% in the 2.5 mg/kg cohort and 34% in the 3.4 mg/kg cohort. Keratopathy was the most frequent adverse event, occurring in 71% and 77% of patients, respectively. Other ocular toxicities included changes in visual acuity, blurred vision, and dry eye. The U.S. prescribing information for belantamab mafodotin includes a boxed warning for ocular toxicity, and belantamab mafodotin is available only through a restricted program under a Risk Evaluation and Mitigation Strategy. This article summarizes the data and the FDA review process supporting accelerated approval of belantamab mafodotin 2.5 mg/kg intravenously once every 3 weeks. This approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Для цитирования: Baines Andrea C, Ershler Rachel, Kanapuru Bindu, Xu Qing, Shen Guoxiang, Li Liang, Ma Lian, Okusanya Olanrewaju O, Simpson Natalie E, Nguyen Wanda, Theoret Marc R, Pazdur Richard, Gormley Nicole J. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. DOI: 10.1158/1078-0432.ccr-22-0618.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.